VOR - NASDAQ

Vor Biopharma Inc.

VOR·NASDAQ

$13.44

-0.037%

HealthcareBiotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$92.12M

EPS-70.5000

P/E Ratio-0.19

Earnings Date08/11/2026

464.13M

Assets

225%

3Y+55.0%

5Y+511.0%

10Y+45990.0%

628.44M

Total Liabilities

1259%

3Y+1189.0%

5Y+2174.0%

10Y+7984.0%

-164.31M

Total Equity

-270%

3Y-166.0%

5Y-440.0%

10Y+2328.0%

Vor Biopharma Inc. Funding & Solvency Profile

VOR · NASDAQ

Current Assets

Cash & Cash Equivalents396.49M

Net Receivables0.00

Inventory0.00

Other Current Assets2.90M

Total Current Assets458 M

Non-Current Assets

Property, Plant & Equipment3.47M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets2.55M

Total Non-Current Assets6 M

Total Assets

464.13M

Financial Health Analysis

Current Ratio

18.20x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Working Capital

433 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

99% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Vor Biopharma Inc. Balance Sheet

VOR • NASDAQ

Vor Biopharma Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	396.5M	81.9M	31.4M	57.7M	119.8M	48.5M	6.5M	929K
Short-Term Investments	58.7M	10M	105.8M	172.5M	87.7M	0.0	0.0	0.0
Cash & Short-Term Investments	455.2M	91.9M	137.2M	230.2M	207.5M	48.5M	6.5M	929K
Prepaids	0.0	4.2M	3.2M	4.4M	4.8M	467K	868K	7K
Other Current Assets	2.9M	380K	475K	2.3M	2.1M	100K	205K	0.0
Total Current Assets	458.1M	96.5M	140.8M	237M	214.4M	49.1M	7.5M	936K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	3.5M	41.6M	50.1M	57.1M	22.5M	21.8M	728K	71K
Long-Term Investments	0.0	0.0	2.4M	2.4M	0.0	1.6M	1.6M	0.0
Tax Assets	0.0	0.0	11.7M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	2.6M	4.8M	4.8M	2.9M	5.7M	3.4M	0.0	0.0
Total Non-Current Assets	6M	46.4M	69M	62.4M	28.2M	26.8M	2.3M	71K
Total Assets	464.1M	142.9M	209.8M	299.4M	242.6M	75.9M	9.8M	1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.1M	1.5M	815K	1.8M	1.5M	2.4M	693K	38K
Accounts Payable	5.1M	1.5M	815K	1.8M	1.5M	2.4M	693K	38K
Accrued Expenses	4.4M	12.9M	6M	3.1M	6.3M	2.7M	593K	82K
Short Term Debt	280K	0.0	3.8M	0.0	0.0	863K	0.0	4.5M
Capital Lease Obligations (Current)	0.0	4.2M	0.0	3.3M	1.8M	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4M
Other Current Liabilities	15.3M	0.0	5M	4.9M	434K	4.3M	900K	3.2M
Total Current Liabilities	25.2M	18.6M	15.6M	13.1M	10.2M	10.2M	2.2M	7.8M
NON-CURRENT LIABILITIES
Deferred Tax Liabilities (Non-Current)	0.0	0.0	11.7M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	600.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	603.3M	27.6M	43.5M	35.6M	16.2M	17.4M	0.0	0.0
Capital Lease Obligations	2.7M	31.8M	31.8M	38.9M	18M	17.4M	0.0	0.0
Total Liabilities	628.4M	46.2M	59.1M	48.8M	26.3M	27.6M	2.2M	7.8M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	107.3M	25.1M	2K
Common Stock	18K	13K	7K	7K	4K	1K	0.0	0.0
Additional Paid-In Capital	988.6M	553.6M	490.9M	473.6M	346.4M	2.2M	458K	279K
Retained Earnings	-1.2B	-457M	-340.1M	-222.2M	-130.1M	-61.2M	-17.9M	-7M
Accumulated Other Comprehensive Income/Loss	41K	22K	-77K	-770K	0.0	0.0	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	-1K	0.0	0.0	0.0
Total Stockholders' Equity	-164.3M	96.7M	150.7M	250.6M	216.3M	48.3M	7.6M	-6.8M
Total Equity	-164.3M	96.7M	150.7M	250.6M	216.3M	48.3M	7.6M	-6.8M
SUMMARY
Total Liabilities & Equity	464.1M	142.9M	209.8M	299.4M	242.6M	75.9M	9.8M	1M
Total Investments	58.7M	10M	108.2M	175M	87.7M	1.6M	1.6M	0.0
Total Debt	3M	31.8M	35.7M	38.9M	18M	18.3M	0.0	4.5M
Net Debt	-393.5M	-50.1M	4.3M	-18.8M	-101.8M	-30.2M	-6.5M	3.5M
Shares Outstanding	6,334,164	6,334,164	6,334,164	6,334,164	6,334,164	6,334,164	6,334,164	6,334,164

SEC Filings

VOR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
S-3 S-3 N/A	April 27, 2026	April 27, 2026		View Filing
DEF 14A DEF 14A 2026 N/A	April 27, 2026	April 23, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 30, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 27, 2026	March 26, 2026	2026	View Filing
S-3 S-3 N/A	January 29, 2026	January 29, 2026		View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2025 N/A	January 02, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 18, 2025	December 15, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 09, 2025	December 05, 2025	2025	View Filing

Showing 1 to 10 of 85 filings

Related Guides

Blog Categories

Continue your VOR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.